Seattle Genetics junks SGN-15 cancer program, shifts focus

A Phase II trial of SGN-15 in combination with Taxotere against lung cancer demonstrated "an encouraging trend," but Seattle Genetics says it will dump any further research into the therapy in order to concentrate on others in its pipeline.

"Our clinical data confirm what we observed in our preclinical studies, which indicated that dosing SGN-15 prior to Taxotere enhances the therapeutic effect of the combination as compared to concurrent administration," said Clay B. Siegall, PhD, president and CEO at Seattle Genetics. "However, given the strength and diversity of the other products in our pipeline, we have decided not to continue development of SGN-15 and instead will evaluate out-licensing opportunities for the program."

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.